Viral vectors are a critical part of gene therapies and genetic medicines, which are the cornerstone of precision medicines to cure rare diseases, cancers, and genetic disorders. Traditional bioprocessing, however, is tedious, less flexible, batch-based, and heavily manual; as a result, manufacturing processes involve high costs, scalability issues, and variability. Digital biomanufacturing represents a transformational shift in the development of viral vectors. The convergence of digital technologies and biomanufacturing makes the process more resilient, efficient, and adaptive. The demand for digital viral vector manufacturing is being driven by the intense competition in gene and cell therapies.
•    How is the one-time curative potential of major treatments allowing early adopters to gain more patient share over late entrants?
•    With the importance of speed and timeline adherence, what steps can your team take to capitalize on early launches and gain a competitive advantage?
•    What are the growth opportunities for digital tools that make processes more productive and scalable?